Clinical Trials Browser

INDUSTRY × INCB039110 × Thoracic × Clear all

Carcinoma, Non-Small-Cell Lung

NCT02917993 2026-02-09

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Phase 1/2 Completed

59 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Inhibition, Psychological, Lung Neoplasms, Neoplasm Metastasis

NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Phase 1 Completed

159 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT02355431 2019-03-08

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Phase 2 Withdrawn

Other hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Hematologic Neoplasms

Clinical Trials

Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations